You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

FDA reviews Biogen’s hemophilia A drug

George Scangos is CEO of Weston-based Biogen Idec.

Reuters/File 2011

George Scangos is CEO of Weston-based Biogen Idec.

Biogen Idec Inc. said the Food and Drug Administration has agreed to review its experimental drug Eloctate as a treatment for hemophilia A. It would be injected once or twice a week; existing treatments are taken three or four times a week. Hemophilia A, which is inherited, occurs in one of 5,000 male births. Those with the disease don’t have enough factor VIII, a blood clotting protein. The FDA in March started reviewing Biogen Idec’s Alprolix for hemophilia B, which is even rarer and caused by a different deficiency.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of